Agilon health stock has had a very strong year so far, yet the valuation checks still point to shares screening cheap on several measures. For investors looking at agilon health today, the combination of a sharp year to date gain and a high value score raises questions about how much upside, if any, is already reflected in the price.

• Year to date, agilon health is up about 459%, which is an unusually large move that can leave the stock more sensitive to shifts in expectations.
• Recent news about stronger revenues, profitability gains and a growing customer base may support confidence in the business model, while any slowdown in adding new customers or in operational improvements could weigh on how much investors are willing to pay.
• On broader valuation checks, agilon health earns a high value score of 5, which suggests the stock still leans cheap relative to the fundamentals those models track.

The issue now is whether agilon health’s current price fairly reflects this mix of strong recent returns and a valuation profile that still screens as undervalued.

Compare agilon health’s sharp move with other stocks that pair strong recent action with solid fundamentals using our hand picked 46 high quality undervalued stocks.

Is agilon health Still Cheap on Sales?

P/S can be a useful check for agilon health because the business is still building towards consistent free cash flow and earnings. On this measure, agilon health trades on a P/S of about 0.3x, which is well below the Healthcare industry average of about 1.5x and also below the peer group average of about 1.8x. That means investors are currently paying much less per dollar of revenue than is typical across similar stocks.

The fair P/S ratio implied by the model is about 0.5x, which is still above the current multiple. Because recent results highlighted higher revenues and raised guidance, the gap between agilon health’s current P/S and this fair level suggests the share price is not fully reflecting the revenue base that the company is building. The discount is visible both against simple industry benchmarks and against this more tailored fair ratio.

On the P/S multiple, agilon health stock appears undervalued relative to both its fair ratio and sector peers.

The agilon health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where agilon health's valuation puzzle leaves off and explain which assumptions on future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price on the Community page. Each narrative ties a specific fair value to a clear story about agilon health's possible catalysts and risks, so you can track which version of events appears to be unfolding over time.

The agilon health community is split between a margin recovery story and a thesis that rich expectations collide with execution risk.

Bull case: 15% undervalued

"Expansion of clinical pathways, successful scaling of chronic disease management programs, and strong PCP and patient retention reinforce agilon health's operational leverage..."

Bear case: 328% overvalued

"Delayed profitability, execution missteps, and difficulty in risk adjustment have constrained agilon health's margin and earnings improvement despite favorable demographic and policy trends..."

Do you think there's more to the story for agilon health? Head over to our Community to see what others are saying!

The Bottom Line

For agilon health, the key question is whether the current discount on revenue fairly compensates you for the execution risks that the bear case highlights. The stock still screens as undervalued on P/S, yet the sharp move this year means expectations can reset quickly if margins or operational delivery fall short. The crux now is whether agilon health can turn its revenue base into consistent, higher quality earnings. If that happens, today’s multiple could look conservative. If it stalls, the apparent discount may prove to be a value trap rather than a clear opportunity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.